Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 1, 2007, Pages 12-19

  Zimmermann, Jens ^a   Schlegelmilch, Ronald ^a   Mazur, Dago ^b   Seiler, Dan ^b   Vens Cappell, Bernhard ^b  

^a Dr Kade Pharmazeutische Fabrik GmbH   (Germany)

^b Scope International   (Germany)

Author keywords

CAS 137 58 6; Hemorrhoids; Lidocaine ointment, multiple dose, pharmacokinetics, systemic safety; LidoPosterine Salbe; Local anesthetics; Posterisan akut Rektalsalbe

Indexed keywords

ESCHERICHIA COLI VACCINE; LIDOCAINE;

ABDOMINAL PAIN; ANUS FISSURE; APPLICATION SITE BURNING; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DIPLOPIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; FLATULENCE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMORRHOID; HUMAN; INSOMNIA; MALE; NAUSEA; NECK PAIN; PAIN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TONSILLITIS; WEAKNESS;

EID: 33846807577     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296580     Document Type: Article

References (32)

1. Gilman AG, Goodman LS, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing; 1980.
2. Product Information: Xylocaine®, lidocaine, Astra USA, Inc, Westborough MA, PI revised 1/99, reviewed 3/2000.
3. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973;78:499-508.
4. Friskopp J, Huledal G. Plasma levels of lidocaine and prilocaine after application of Oraqix®, a new intrapocket anesthetic, in patients with advanced periodontitis. J Clin Periodontol. 2001;28:425-429.
5. Collinsworth KA, Kalman SM, Harrison DC. The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation. 1974;50:1217-1230.
6. Conklin KA. Pharmacology of Local Anesthetics. J Amer Ass Nurse Anesth. 1987;55:36-44.
7. Cousins MJ, Mather LE. Clinical Pharmacology of Local Anaesthetics. Anaesth Intensive Care. 1980;8:257-277.
8. Hieble JP, Ruffolo RR. Local anesthetics. In: Munson PL, ed. Principles of pharmacology. New York: Chapman & Hall; 1995. p. 191-200.
9. Svensson P, Bjerring P, Arendt-Nielsen L, Kaaber S. Hypoalgesic effect of EMLA and lidocaine gel applied on human oral mucosa: quantitative evaluation of sensory and pain thresholds to argon laser stimulation. Anesth Prog. 1992; 39:4-8.
10. Scott DB, Cousins MJ. Neural Blockade in Clinical Anesthesia and Management of Pain. In: Cousins MJ, Bridenbaugh O, eds. Clinical Pharmacology of Local Anesthetic Agents. Philadelphia-Toronto: J. B. Lippincott; 1980.
11. Product Information: Lidoderm, lidocaine 5% patch. Endo Pharmaceuticals Inc., Chadds Ford, PA, PI revised 3/99, reviewed 3/2000.
12. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs. 2000; 59:245-249.
13. Benowitz NL, Meister W. Clinical Pharmacokinetics of Lignocaine. Clin Pharmacokinet. 1978;3:177-201.
14. Leynadier F. Les accidents des anesthésiques locaux. La Rev Pract - Méd Gén. 1991;5:1-5.
15. Bharti N, Shende D. Transient cardiopulmonary arrest following retrobulbar block with lignocaine. Anaesth Intens Care. 2002;30:388-389.
16. Bassett IB, Delaney TA, Freeman S. Can injected lignocaine cause allergic contact dermatitis? Aust J Dermatol. 1996;37:155-156.
17. Karim A, Ahmed S, Siddiqui R, Mattana J. Methemoglobinemia complicating topical lidocaine used during endoscopic procedures. Am J Med. 2001;111:150-153.
18. Brisman M, Ljung BML, Otterbom I, Larsson LE, Andréasson SE. Methaemoglobin formation after the use of EMLA cream in term neonates. Acta Paediatr. 1998;87:1191-1194.
19. Note for Guidance on Good Clinical Practice CPMP/ ICH/135/95.
20. Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, Cronin E, et al. Terminology of contact dermatitis. Acta Dermatovener. 1970;50:287-292.
21. Shah VP, Midha KK, Digne S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet. 1991;16:249-255.
22. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation: A revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
23. Guidance for Industry: Bioanalytical Method Validation. FDA 2001.
24. SAS Institute Inc. SAS Procedures Guide, Release 6.08 Edition. The UNIVARIATE Procedure. Cary, NC: SAS Institute Inc.; 1988, p. 405.
25. Steinijans VW, Diletti E. Statistical analysis of bioava lability studies: parametric and nonparametric confidence intervals. Eur J Clin Pharmacol. 1983;24:127-136.
26. De Jong RH, Bonin JD. Deaths from Local Anesthetic-Induced Convulsions in Mice. Anesth Analg. 1980;59:401-405.
27. Munson ES, Tucker WK, Ausinsch B, Malagodi MH. Etidocaine, bupivacaine, and lidocaine seizure thresholds in monkeys. Anesthesiology. 1975;42:471-478.
28. Gianelly RE, von der Groeben JO, Spivack AP, Harison DC. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. New Engl J Med. 1967; 277:1215-1219.
29. Lie KI, Wellens HJ, van Capelle FJ. Durrer D. Lidocaine in the prevention of primary ventricular fibrillation. New Engl J Med. 1974;291:1324-1326.
30. Stymne B, Lillieborg S. Plasma concentrations of lignocaine and prilocaine after a 24-h application of analgesic cream (EMLA) to leg ulcers. Br J Dermatol. 2001;145:530-534.
31. Serpell MG, Gupta R. Plasma concentration of lignocaine after rectal administration. Anaesth. 1993;48:926-927
32. Beckett AH, Burgess CD, Johnston A, Warrington SJ. The systemic availability of a slow release rectal preparation of lignocaine. Br J Clin Pharmacol. 1978 Nov;6(5):442-443.